Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

Sorafenib, a multi-tyrosine kinase inhibitor, kills more effectively the non-metastatic prostate cancer cell line 22Rv1 than the highly metastatic prostate cancer cell line PC3. In 22Rv1 cells, constitutively active STAT3 and ERK are targeted by sorafenib, contrasting with PC3 cells, in which these...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kharaziha, P, Rodriguez, P, Li, Q, Rundqvist, H, Björklund, A-C, Augsten, M, Ullén, A, Egevad, L, Wiklund, P, Nilsson, S, Kroemer, G, Grander, D, Panaretakis, T
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3270278/
https://ncbi.nlm.nih.gov/pubmed/22278289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2012.1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados